6533b86dfe1ef96bd12caaaf
RESEARCH PRODUCT
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
Gl BannaMassimo Di MaioA FolladorE CollovàJ MenisSilvia NovelloE Bria Isa Co AuthorsM AiroldiD AmorosoA ArdizzoiaG AurilioE BajettaP BallardiniF BarbieriE BarlettaMl BalzelloniU BassoI BernardiniC BoniV BordinS BrettiG BronteC BrunettiS ButiGl BannaM Di MaioA FolladorE CollovàJ MenisS NovelloE Bria Isa Co AuthorsM AiroldiD AmorosoA ArdizzoiaG AurilioE BajettaP BallardiniF BarbieriE BarlettaMl BalzelloniU BassoI BernardiniC BoniV BordinS BrettiG BronteC BrunettiS ButiL CapannaA ColomboG CondemiD CortinovisM DambrosioC Di FonzoG Di LuccaG DimaA FalzettaA FavarettoF FerraùL GarettoV GebbiaG GenestretiAl GentileF GiovanardiR LabiancaV LorussoG MantovaniO MartelliF MassariM MazzoliG MichettiP MordentiC MucciariniS MunaoA NacciC PoglianiG ProcopioF RiccardiS RizzatoA RossiG RostiP RussoT SaladinoN SalesiD SantangeloT SavaA SavarinoF SpinnatoM TiseoO TomassiL TondulliG ToniniS TuranoMr ValerioF VerderameF ZanelliE. Zanonsubject
OncologyCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentDiseasechemotherapyDeoxycytidinelaw.inventionCarboplatinRandomized controlled trialNon-small cell lung cancerlawCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsPostoperative radiotherapyStage (cooking)Non-Small-Cell LungSurveyVinorelbineOncologyChemotherapy AdjuvantAdjuvantmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPaclitaxelnon-small cell lung cancer; adjuvant; Survey; chemotherapyVinblastineadjuvantInternal medicinemedicineHumansLung cancerNeoplasm StagingCisplatinAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryCarcinomamedicine.diseaseGemcitabineSurgeryAdjuvant chemotherapyRadiation therapyLung NeoplasmRegimenHealth Care SurveysAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; SurveyAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; Survey; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Adjuvant; Vinblastine; Vinorelbine; Health Care Surveys; Oncology; Pulmonary and Respiratory Medicine; Cancer ResearchRadiotherapy AdjuvantCisplatinbusinessdescription
Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen. © 2010 Elsevier Ireland Ltd.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-07-01 |